Praha, November 4, 2020 / PRNewswire / – Zentiva received the 2020 Global Generics and Biosimilars Bulletin Award in the category of EMEA Acquisition of the Year. In Q2 2020, during the peak of the first wave of the COVID-19 crisis, Zentiva completed the acquisition of Alvogen CEE which brought together two of the leading branded generic and OTC businesses in the CEE region. The acquisition is already showing indicators of success and is supporting Zentiva’s journey and ambition to grow while increasing the company’s commercial footprint.
“Zentiva has been honored to receive this prestigious award and recognition. The combination of Alvogen and Zentiva at CEE creates a new branded generic, original brand and OTC powerhouse in the region. The new joint team is talented, fast-moving and ambitious that seeks to induct Zentiva as a reliable and high-performance commercialization partner through in-house product development and strategic partnerships with leading companies.” What was said Nick Hagar, Chief Executive Officer, Zentiva.
Zentiva is a producer of high quality inexpensive medicines in which patients are served. Europe and beyond. With a dedicated team of over 4,500 people and a network of production sites – including the leading sites Prague, Bucharest, And Ankleshwar – Zentiva strives to become the champion of branded and generic drugs Europe To better support the daily health needs of the people.
It is our aspiration in Zentiva that health care should be a right and not a privilege. More than ever, people need higher quality affordable medicines and better access to healthcare. We work in partnership with physicians, pharmacists, wholesalers, regulators, and governments, providing day-to-day solutions to all of us. Learn more www.zentiva.com.
Head of communication
Zentiva Group, as
U Kabelovny 529/16, Dolny Mocholupi, 102 00 Prague 10
Cell: (+420) 727 873 159
E-mail: [email protected]
Content is by PR Newswire. Tech Media is not responsible for the content provided or any link related to this content. Tech Media is not responsible for the accuracy, timeliness or quality of content.